HomeBUSINESS
BUSINESS

CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
(Sep.22.2017)

CSL Limited CEO Paul Perreault
Global plasma behemoth CSL Limited has allocated a growing proportion of its spending to new drug development to keep delivering innovation despite its R&D-to-sales ratio being lower than those of big pharma peers, visiting CEO Paul Perreault said at a Tokyo media forum ...
(LOG IN FOR FULL STORY)

News Calendar